Skip to main content
SpringerLink
Log in

Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium

A Prospective, Open-Label, Observational Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

Despite a lack of clear recommendations to guide decision-making, reductions in enoxaparin sodium dosage in the elderly and in patients with mild and moderate renal dysfunction are common in patients with acute coronary syndrome.

Objective

To evaluate whether weight, age and renal function are associated with anti-factor Xa activity and with bleeding in elderly patients treated with enoxaparin sodium.

Method

This was a prospective observational study of 156 elderly patients admitted consecutively to a general internal medicine ward with creatinine clearance >30 mL/min who were treated with enoxaparin sodium twice daily. Anti-factor Xa activity and bleeding events were documented in all patients. Statistical analyses were conducted to determine the effects of clinical characteristics such as renal dysfunction, age and bodyweight on these parameters.

Results

156 patients (60% males, mean age 71.0 ± 15.98 years) were studied. Therapeutic anti-factor Xa was observed in 85.3% of patients treated with enoxaparin sodium 0.61–0.8 mg/kg/12h, and in 82.6% of patients treated with enoxaparin sodium 0.81–1.1 mg/kg/12h. Minor or major bleeding was observed in 5.8% of patients, and was associated with a lower mean bodyweight (61.89 ± 13.35 vs 74.30 ± 13.24 kg for patients with no bleeding; ? = 0.014). Bodyweight ≤55 kg was associated with bleeding with an odds ratio of 5.63 (95% CI 1.2, 25, p = 0.025).

Conclusion

Low bodyweight is associated with a greater risk of bleeding despite a reduction in enoxaparin sodium dose according to weight. This finding supports the possibility that low bodyweight is an independent risk factor for enoxaparin sodium-related bleeding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III

Similar content being viewed by others

References

  1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001 Jan; 119 (1 Suppl.): 64S–94S

    Article  CAS  Google Scholar 

  2. Braunwald E, Antman E, Beasley J, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2000; 36: 970–1062

    Article  CAS  Google Scholar 

  3. Bertrand M, Simoons M, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Eur Heart J 2002; 23: 1809–40

    Article  Google Scholar 

  4. Levine M, Jent M, Hirsh J, et al. A comparison of low molecular-weight heparin administered primarily at home with un-fractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81

    Article  CAS  Google Scholar 

  5. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109(8): 997–1003

    Article  CAS  Google Scholar 

  6. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355(10): 1006–17

    Article  CAS  Google Scholar 

  7. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474–82

    Article  Google Scholar 

  8. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41(1): 8–14

    Article  CAS  Google Scholar 

  9. Macie C, Forbes L, Foster GA, et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004; 125: 1616–21

    Article  Google Scholar 

  10. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72(3): 308–18

    Article  CAS  Google Scholar 

  11. Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542–52

    Article  CAS  Google Scholar 

  12. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143(5): 753–9

    Article  CAS  Google Scholar 

  13. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144(9): 673–84

    Article  CAS  Google Scholar 

  14. Food and Drug Administration. Enoxaparin injection drug approval: 2004 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2004/lovenox_PI.pdf. [Accessed 2005 May 6]

  15. Lacy CF, Armstrong LL. Drug information handbook. 16th ed. Hudson (OH): Lexicomp, Inc., 2007

    Google Scholar 

  16. Enoxaparin sodium investigator brochure. 12th ed. Bridgewater (NJ): Avenus Pharma, 2003

  17. Henderson MC, White RH. Anticoagulation in the elderly. Curr Opin Pulm Med 2001; 7(5): 365–70

    Article  CAS  Google Scholar 

  18. Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing 1984; 13(2): 120–3

    Article  CAS  Google Scholar 

  19. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110(4): 392–8

    Article  CAS  Google Scholar 

  20. Antman EM, Morrow DA, McCabe CH, et al. ExTRACT-TIMI 25 investigators: enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354(14): 1477–88

    Article  CAS  Google Scholar 

  21. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004 Oct; 148(4): 582–9

    Article  CAS  Google Scholar 

  22. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56(1): 96–103

    Article  CAS  Google Scholar 

  23. Ellis SG, Elliott J, Horrigan M, et al. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996; 78(6): 642–6

    Article  CAS  Google Scholar 

  24. Barba R, Marco J, Martin-Alvarez H, et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005; 3(5): 856–62

    Article  CAS  Google Scholar 

  25. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294(24): 3108–16

    Article  CAS  Google Scholar 

  26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    Article  CAS  Google Scholar 

  27. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2000; 36: 970–1062

    Article  CAS  Google Scholar 

  28. Thavendiranathan P, Bagai A, Ebidia A, et al. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med 2005 Jun; 20(6): 520–4

    Article  Google Scholar 

  29. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8(6): 859–67

    Article  CAS  Google Scholar 

  30. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103(5): 658–63

    Article  CAS  Google Scholar 

  31. Wedick NM, Barrett-Connor E, Knoke JD, et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. J Am Geriatr Soc 2002; 50(11): 1810–5

    Article  Google Scholar 

  32. Newman AB, Yanez D, Harris T, et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001; 49(10): 1309–18

    Article  CAS  Google Scholar 

  33. Covinsky KE, Martin GE, Beyth RJ, et al. The relationship between clinical assessments of nutritional status and adverse outcomes in older hospitalized medical patients. J Am Geriatr Soc 1999; 47(5): 532–8

    Article  CAS  Google Scholar 

  34. Maurer MS, Luchsinger JA, Wellner R, et al. The effect of body mass index on complications from cardiac surgery in the oldest old. J Am Geriatr Soc 2002; 50(6): 988–94

    Article  Google Scholar 

  35. Monreal M, Falgá C, Valle R, et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006 Dec; 119(12): 1073–9

    Article  Google Scholar 

  36. Cook LM, Kahn SR, Goodwin J, et al. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007 May; 5(5): 937–41

    Article  CAS  Google Scholar 

  37. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001 Feb 6; 134(3): 191–202

    Article  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Medicine, Hadassah University Hospital, Jerusalem, Israel

    Avi Levin, Moshe Ben-Artzi, Pazit Beckerman, Guy Haber, Arie Ben-Yehuda &  Mordechai Muszkat

  2. Department of Hematology, Hadassah University Hospital, Jerusalem, Israel

    David Varon

  3. Division of Clinical Pharmacology, Hadassah University Hospital, Jerusalem, Israel

    Mordechai Muszkat

Authors
  1. Avi Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moshe Ben-Artzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pazit Beckerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guy Haber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Varon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arie Ben-Yehuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mordechai Muszkat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mordechai Muszkat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levin, A., Ben-Artzi, M., Beckerman, P. et al. Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium. Drugs Aging 26, 77–85 (2009). https://doi.org/10.2165/0002512-200926010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0002512-200926010-00006

Keywords

Search

Navigation